Skip to Content
 
Center for International Blood and Marrow Transplant Research

P-5561

Main Content

Return to Listing

Hematology-American Society of Hematology Education Program | 2021

Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors.

Epperla N, Hamadani M

PubMed
PMID: 34889401

Abstract
Related Articles

CIBMTR Study #: CIBMTR_NA

Working Committee: Lymphoma